Research & Development

6% of revenue invested in R&D. 40+ scientists. 12 patents. From molecule to market — we develop formulations that make a difference.

40+
Scientists
12
Patents
15
ANDA Filings
50+
BE Studies
Expertise

R&D Capabilities

Formulation Development

Oral solids (IR, SR, MR, EC), liquids, semi-solids, injectables, dry syrups. Taste-masking, stability enhancement, bioavailability improvement.

Analytical Method Development

HPLC, GC, UV-Vis, FTIR method development and validation per ICH Q2(R1). Forced degradation and impurity profiling.

Stability Studies

ICH Q1A/Q1B compliant. Accelerated (40°C/75% RH), intermediate, and long-term conditions. Photostability per ICH Q1B.

Bioequivalence Support

Study design, CRO coordination, and regulatory filing support for BE studies. 50+ successful BE studies completed.

Regulatory Filing

CTD/eCTD dossier preparation for India (CDSCO), US (ANDA), EU (ASMF/CEP), Africa (WHO PQ), and other regulated markets.

Patent & IP

12 patents filed. FTO analysis, patent landscape mapping, and non-infringing formulation strategies.

Pipeline

Product Pipeline

Filed / Under Review

Sitagliptin 50mg/100mg (ANDA)Dapagliflozin 5mg/10mg (ANDA)Apixaban 2.5mg/5mg (ANDA)Empagliflozin + Metformin (CDSCO)

Bioequivalence Stage

Rivaroxaban 10mg/15mg/20mgVildagliptin + MetforminTeneligliptin 20mg

Formulation Development

Semaglutide Oral (novel delivery)Linagliptin 5mgSacubitril/ValsartanDolutegravir 50mg (WHO PQ)